Calendario›TRAW›ON 01910.Na · ONTRAC

ON 01910.Na · ONTRAC

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Ensayo de Traws Pharma, Inc. en Metastatic Pancreatic Adenocarcinoma (del registro, en inglés).

Fase

Fase 3

Estado

Completado

Participantes

160

previstos

Centros

46

Fin del objetivo primario

jun 2015

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, abierto. Comenzó en may 2011.

Qué mide

Survival (del registro, en inglés) (18 meses)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe question being asked in this study is: Will patients with advanced pancreatic cancer live significantly longer if they are treated with a combination of Gemcitabine and ON 01910.Na than if they are treated with Gemcitabine alone? There are two parts to this study. In the first part of the study, patients with metastatic pancreatic cancer who have received no prior chemotherapy for this disease will be assigned by chance either to the group that will be treated with both Gemcitabine and ON 01910.Na (about 100 patients will be in this group) or, to the group that will be treated with Gemcitabine only (about 50 patients will be in this group). How long patients survive in the 2 groups will be compared. If it looks like there is no difference between the groups, the study will stop. If it looks like patients in the group that were treated with both Gemcitabine and ON 01910.Na survive longer, the study will continue into a second part where more patients will be treated in order to confirm and better understand the findings of the first part of the study.

Más ensayos de TRAW

Todos los de TRAW, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT01360853), actualizada en ago 2016.